However, some NSCLC patients experience immune-related adverse events, including severe diarrhea, colitis, dermatitis, hepatic damage, or thyroiditis, following PD-1/PD-L1 treatment (4) Managing these adverse effects can be challenging and may involve immunosuppressives, steroids, and withdrawal of ICI therapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.